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Evidence from Framingham studies showed that some disor-
ders and conditions (such as hypertension, hyperlipidaemia,
smoking, diabetes, old age, and male sex) are particularly
useful to estimate the cardiovascular (CV) risk of acute
ischemic events [1] and are currently considered as the
“traditional” cardiovascular risk factors. This led to the
development of several clinically based CV risk stratiﬁcation
tools, and the Framingham risk score is one of the most
commonly used CV risk stratiﬁcation tools nowadays [2].
However, these “traditional” cardiovascular risk factors were
shown to be suboptimal for proper CV risk stratiﬁcation due
to low speciﬁcity and sensitivity [3–6]. Therefore, a novel
concept of “global” cardiovascular vulnerability has been
suggested to better predict acute cardiovascular events [7, 8].
Interestingly, this approach was particularly focused on “the
clinical and laboratory complexity of the patient” instead of
“a single risk factor.” Several pathophysiological parameters
havebeen proposed asnewcardiovascularrisk factorspoten-
tially improving the assessment of patient vulnerability [7,
8].Althoughsomecontroversiesstillexist,theatherosclerotic
role of inﬂammatory biomarkers (such as C-reactive protein
(CRP), cytokines, and chemokines) [9–12] has been shown
within atherosclerotic plaques, in the systemic circulation or
in the peripheral ischemic tissues in both in vivo and in vitro
models. More recently, novel inﬂammatory mediators (such
as circulating autoantibodies and hormones) have been
also identiﬁed [13, 14]. These soluble mediators have been
shown to trigger several atherosclerotic functions of both
inﬂammatory and vascular cells [15]. On the other hand, the
mobilization ofprotective cellsubsetsmight alsocounterbal-
ance atheroprogression, thus limiting the chronic inﬂamma-
tory processes and improving cardiovascular outcomes [16].
These protective aspects might be particularly relevant when
atherosclerosis is associated with concomitant inﬂammatory
conditions (such as rheumatoid arthritis, infections, and
diabetes), which seem to further accelerate atherogene-
sis towards ﬁnal acute ischemic complications or arterial
aneurysms[17–19].Thisspecialissuefocusedonnewsoluble
mediators as promising candidates to better assess the car-
diovascular risk. Importantly, the limitations of the potential
clinical use of these systemic and intraplaque inﬂammatory
molecules inﬂuencing atheroprogression have also been dis-
cussed.Inparticular,E.Lupiaandcoworkersrevisedtheclin-
ical role of thrombopoietin (a humoral growth factor acti-
vating platelets) as a promising biomarker of cardiovascular
injury.P.Kunesandcolleaguesdevelopedinterestingﬁndings
on the controversial role of pentraxin family (which includes
CRP) in the inﬂammatory response. The authors focused on2 Mediators of Inﬂammation
the newly discovered pentraxin 3 and suggested paradoxical
issues that will probably be validated in the near future. Drs.
D. Vasic and the D. Walcher from the University of Ulm
(Germany) revised the potential proatherosclerotic activity
of C-peptide as a predictor of cardiovascular risk in diabetic
subjects. This paper focused on a hot-topic issue in cardio-
vascular research. In fact, only very recently, C-peptide (pre-
viouslyconsideredasaproductofcleavageofproinsulin)has
been proposed as an active factor favouring atherosclerosis.
Despite some limitations on the molecular mechanisms (the
C-peptide receptor remains to be identiﬁed), this molecule
might activate diﬀerent leukocyte subsets in atherogenesis.
Among these cells,the diﬀerent types of macrophages appear
as a relevant target for inﬂammatory mediators. T. Gui and
coworkers discussed this issue and provided an interesting
and comprehensive review on the impact of macrophages
in both early and advanced phases of atherogenesis. The
authors also suggested these cells as promising biomark-
ers of plaque vulnerability. Another review article of the
present issue mainly focused on the proteolytic mechanisms
regulating intraplaque remodelling potentially favouring the
formation of abdominal aortic aneurysms. Drs. Z.- Z. Li and
Q.-Y. Dai focused on direct activities mediated by nicotine
via its receptor (nicotinic acetylcholine receptor) on plaque
inﬂammation, angiogenesis, and smooth muscle cell dys-
function. The paper of Z. Qu and colleagues further devel-
oped the proinﬂammatory reactions underlying abdominal
aortic aneurysm formation in advanced atherosclerosis.
Some receptors of sphingosine-1-phosphate (S1P, a recently
discovered lysophospholipid) were shown to play a crucial
roleinhumanabdominalaortaaneurysmsascomparedwith
normal aorta control tissues. In particular, S1P3 receptor
was signiﬁcantly upregulated in human abdominal aortic
aneurysms, while S1P2 receptor was downregulated as
compared to normal aortic samples. Although the molecular
mechanisms remain unexplored (parallel expression of other
inﬂammatory mediators was not investigated), this obser-
vational study identiﬁed a potential novel cardiovascular
biomarker (S1P) in advanced atherosclerosis. Diﬀerently
from this paper, K.-Karatolios and coworkers focused their
study on well-known cytokines and growth factors. Surpris-
ingly, the authors showed that the levels of vascular endothe-
lialgrowthfactor(VEGF)andhumanbasicﬁbroblastgrowth
factor(bFGF)inpericardialeﬀusionsofpatientswithautore-
activeorviralinﬂammationweresigniﬁcantlyhigherascom-
pared to patients with coronary artery disease (CAD). No
signiﬁcant diﬀerence was shown for inﬂammatory cytokines.
Although the underlying molecular mechanisms remain to
be investigated, these two growth factors might be more
promising biomarkers of pericardial inﬂammation than
“traditional” cytokines. After a diﬀuse discussion on soluble
mediators potentially increasing the cardiovascular risk, R.
Wyderka and coworkers focused their investigation on the
mobilization of protective CD34+CXC4+ stem/progenitor
cells in humans after an acute myocardial infarction. The
authors clearly showed that this process was positively
correlated with the improvements of values of the left
ventricularejection fraction at1-yearof followup, suggesting
a beneﬁcial activity of these cells in myocardial repair.
In both inﬂammatory micro- and macroenvironments
characterizing atherosclerosis, some tissues might also pro-
duce some unexpected molecules potentially contrasting
with physiological paradigms. M. L. Sirico and coworkers
showed that human adipocytes can express and synthesize
albumin. This paper was selected to highlight the poten-
tialities of adipose tissue as an inﬂammatory organ capable
of ectopically producing a large variety of mediators during
atherogenesis. The present issue includes by the paper of
C. Falcone and colleagues investigating the potential activity
as biomarkers of soluble Receptor for Advanced Glycation
End products (sRAGE) in patients with hypertension and
increased cardiovascular risk. The authors showed that
antihypertensive treatments might aﬀect sRAGE plasma
levels. All the papers included in the present issue focused
on both novelty and limitations of promising inﬂamma-
tory biomarkers that in the near future might be used
in the clinical practice to improve cardiovascular disease
prevention. We hope that the reader will ﬁnd some useful
inputs for developing research and updating knowledge on
cardiovascular pathophysiology.
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